Robertson G, Fleming A, Williams MC, Trucco E, Quinn N, Hogg R, McKay GJ, Kee F, Young I, Pellegrini E, Newby DE, van Beek EJR, Peto T, Dhillon B, van Hemert J, MacGillivray TJ. Association between hypertension and retinal vascular features in ultra-widefield fundus imaging. Open Heart. 2020 Jan 8;7(1):e001124. doi: 10.1136/openhrt-2019-001124
Wilson M, Lucas A, Cameron A, Luo M. Budget impact of adding vedolizumab to a health plan formulary as a first-line biologic option for ulcerative colitis and crohn's disease. Am Health Drug Benefits. 2018 Jul;11(5):253-62.
Beillat M, Brown TM, DiBenedetti DB, Naber D. Patient and caregiver perspectives on the Heinrichs-Carpenter Quality of Life Scale and the Subjective Well-being Under Neuroleptics-Short Form. J Psychiatry Psychiatric Disord. 2017 May;1(3):109-26.
Harris JB, Ward MA, Schwab P. Is response-guided therapy being applied in the clinical setting? The hepatitis C example. Am Health Drug Benefits. 2015 Feb;8(1):22-8.
Sacco P, Capkun-Niggli G, Zhang X, Jose R. The economic burden of fragile x syndrome: healthcare resource utilization in the United States. Am Health Drug Benefits. 2013 Mar;6(2):73-83.
Lennert B, Bibeau W, Farrelly E, Sacco P, Schoor T. Assessment of treatment patterns and patient outcomes in levodopa-induced dyskinesias (ASTROID): a US chart review study. Am Health Drug Benefits. 2012 Sep;5(6):347-58.
Meyers J, Classi P, Wietecha L, Candrilli S. Economic burden and comorbidities of attention-deficit/hyperactivity disorder among pediatric patients hospitalized in the United States. Child Adolesc Psychiatry Ment Health. 2010 Dec 1;4:31.